CN111450030A - 一种藻酸盐肌肤护理乳液的制备方法 - Google Patents
一种藻酸盐肌肤护理乳液的制备方法 Download PDFInfo
- Publication number
- CN111450030A CN111450030A CN202010331358.8A CN202010331358A CN111450030A CN 111450030 A CN111450030 A CN 111450030A CN 202010331358 A CN202010331358 A CN 202010331358A CN 111450030 A CN111450030 A CN 111450030A
- Authority
- CN
- China
- Prior art keywords
- stock solution
- solution
- ointment
- skin care
- emulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 68
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 229940072056 alginate Drugs 0.000 title claims abstract description 43
- 235000010443 alginic acid Nutrition 0.000 title claims abstract description 43
- 229920000615 alginic acid Polymers 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000011550 stock solution Substances 0.000 claims abstract description 81
- 239000002674 ointment Substances 0.000 claims abstract description 41
- 239000000243 solution Substances 0.000 claims abstract description 36
- 239000012752 auxiliary agent Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 34
- 239000011159 matrix material Substances 0.000 claims description 31
- 239000003755 preservative agent Substances 0.000 claims description 27
- 230000002335 preservative effect Effects 0.000 claims description 27
- 239000008213 purified water Substances 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 18
- 239000000758 substrate Substances 0.000 claims description 17
- 239000004373 Pullulan Substances 0.000 claims description 12
- 229920001218 Pullulan Polymers 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 12
- 235000019423 pullulan Nutrition 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 241000237858 Gastropoda Species 0.000 claims description 9
- 229920001661 Chitosan Polymers 0.000 claims description 6
- 241000241413 Propolis Species 0.000 claims description 6
- 241000220317 Rosa Species 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 229940069949 propolis Drugs 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- 235000005979 Citrus limon Nutrition 0.000 claims description 5
- 235000014134 echinacea Nutrition 0.000 claims description 5
- 244000133098 Echinacea angustifolia Species 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- 229960004365 benzoic acid Drugs 0.000 claims description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 3
- 229960002645 boric acid Drugs 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- 239000004334 sorbic acid Substances 0.000 claims description 3
- 235000010199 sorbic acid Nutrition 0.000 claims description 3
- 229940075582 sorbic acid Drugs 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims 4
- 244000248349 Citrus limon Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 28
- 208000027418 Wounds and injury Diseases 0.000 abstract description 28
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 239000011241 protective layer Substances 0.000 abstract description 7
- 230000029663 wound healing Effects 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 238000011084 recovery Methods 0.000 abstract description 6
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 5
- 230000004888 barrier function Effects 0.000 abstract description 5
- 238000000354 decomposition reaction Methods 0.000 abstract description 4
- 230000000474 nursing effect Effects 0.000 abstract description 4
- 230000008439 repair process Effects 0.000 abstract description 4
- 230000008467 tissue growth Effects 0.000 abstract description 4
- 230000036573 scar formation Effects 0.000 abstract description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 239000006210 lotion Substances 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 45
- 231100000241 scar Toxicity 0.000 description 11
- 208000032544 Cicatrix Diseases 0.000 description 8
- 230000037387 scars Effects 0.000 description 8
- 244000131522 Citrus pyriformis Species 0.000 description 4
- 230000006378 damage Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 244000260524 Chrysanthemum balsamita Species 0.000 description 1
- 235000005633 Chrysanthemum balsamita Nutrition 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000258180 Echinacea <Echinodermata> Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
- A61K8/988—Honey; Royal jelly, Propolis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种藻酸盐肌肤护理乳液的制备方法,所述方法如下:将原液和助剂按照溶液剂或软膏剂的制备方法制成透明或半透明的剂型为溶液剂或软膏剂的乳液;本发明的藻酸盐肌肤护理乳液的制备方法,采用本发明的制备方法制备的肌肤护理乳液,能够促进组织生长,加快创面愈合,还具有抗菌消炎的作用;将本发明的乳液涂抹于受损皮肤表面,能够在创面表面形成保护层,起物理屏障作用,可用于小创口、擦伤、切割伤等浅表性创面及周围皮肤的护理;还可通过选用不同的原液制备具有养护功效的乳液,能够在创面恢复过程中能够消炎、修复和养护皮肤,促进黑色素分解,消除皮肤色素沉着,减少疤痕的形成。
Description
技术领域
本发明涉及一种藻酸盐肌肤护理乳液的制备方法,属于医疗护理技术领域。
背景技术
外伤、创面异物、创面感染、手术后表面张力过大、烧伤、烫伤等原因会损伤真皮和皮下组织,使真皮内纤维组织及毛细血管网大量增殖,出现局部胶原降解失衡,不断堆积,增生组织越来越高,越来越厚,形成坚硬的、呈不规则形状的肿块,形成疤痕疙瘩,有时甚至会伴有疤痕瘙痒、疼痛等临床症候。疤痕是物理、生物、化学等因素的损害作用于人体皮肤软组织,导致皮肤软组织的严重损伤而不能完全自行正常修复,转由纤维组织替代修复留下的即影响外观又影响功能的局部症状。疤痕增生期的几年时间几乎让患者苦不堪言。而后的萎缩期又使患者面目全非,功能障碍,造成患者极大的身、心双重障碍人们在日常生活、工作中因外伤、烧伤、手术、疗疮等原因在人体表面上遗留下各种各样的疤痕。
目前国内外治疗疤痕多采用局部药物封闭,皮肤移植,手术切除植皮,晶体磨疤术,气囊扩张术,抗体注射,放射治疗,压迫疗法,激素疗法,硅酮类等疗法。有的手术方法治疗成本高、效果不明显,有的治疗疗程长,会增加患者痛苦。虽然近些年来针对祛疤研发的各类产品层出不穷,但成分不明,消费者使用不当,很容易造成肌肤的损伤。
发明内容
为解决上述问题,本发明提出了一种藻酸盐肌肤护理乳液的制备方法,采用本发明的制备方法制备的乳液能够在创面表面形成保护层,起物理屏障作用,可用于小创口、擦伤、切割伤等浅表性创面及周围皮肤的护理。
本发明的藻酸盐肌肤护理乳液的制备方法,所述方法如下:将原液和助剂按照溶液剂或软膏剂的制备方法制成透明或半透明的剂型为溶液剂或软膏剂的乳液。
进一步地,所述原液包括壳聚糖原液、玫瑰花原液、柠檬原液、蜂胶原液、紫锥花原液、蜗牛原液和藻酸盐原液中的至少一种。
进一步地,剂型为溶液剂的所述乳液其助剂包括纯化水、防腐剂、甘油和普鲁兰多糖,且防腐剂占原液重量百分比15~25%,甘油占原液重量百分比20~30%,普鲁兰多糖占原液重量百分比20~30%。
再进一步地,剂型为溶液剂的所述乳液其制备方法具体如下:
第一步,按下列重量百分比的原料备料:原液50~55%,甘油10~25%,普鲁兰多糖10~15%,防腐剂7~15%,余量为纯化水,上述各组分原料重量总计为100%;
第二步,将甘油、防腐剂和适量纯化水混合均匀,再水浴加热至65~80℃,得到溶液剂基质A,待用;
第三步,将普鲁兰多糖和适量纯化水混合均匀,再水浴加热至50~70℃,得到溶液剂基质B,待用;
第四步,当溶液剂基质A和溶液剂基质B处于相同水浴环境时,将溶液剂基质B呈细流状倒入溶液剂基质A中,边加边沿同一个方向搅拌,搅拌均匀后,自然降温至室温,得到混合溶液剂基质,待用;
第五步,将原液加入到混合溶液剂基质中,搅拌均匀,即得剂型为溶液剂的肌肤护理乳液。
进一步地,剂型为软膏剂的所述乳液其助剂包括纯化水、防腐剂和聚丙烯酸钠,且防腐剂占原液重量百分比20~25%,聚丙烯酸钠占原液重量百分比20~47%。
再进一步地,剂型为软膏剂的所述乳液其制备方法具体如下:
第一步,按下列重量百分比的原料备料:原液50~55%,防腐剂7~15%,聚丙烯酸钠10~25%,余量为纯化水,上述各组分原料重量总计为100%;
第二步,将防腐剂和适量纯化水混合均匀,再水浴加热至65~80℃,得到软膏剂基质A,待用;
第三步,将聚丙烯酸钠和适量纯化水混合均匀,再水浴加热至50~70℃,得到软膏剂基质B,待用;
第四步,当软膏剂基质A和软膏剂基质B处于相同水浴环境时,将软膏剂基质B呈细流状倒入软膏剂基质A中,边加边沿同一个方向搅拌,搅拌均匀后,自然降温至室温,得到混合软膏剂基质,待用;
第五步,将原液加入到混合软膏剂基质中,搅拌均匀,即得剂型为软膏剂的肌肤护理乳液。
进一步地,所述防腐剂包括苯甲醇、苯甲酸、水杨酸、硼酸和山梨酸中的至少一种。
进一步地,所述乳液其PH值范围为6~8。
本发明与现有技术相比较,本发明的藻酸盐肌肤护理乳液的制备方法,采用本发明的制备方法制备的肌肤护理乳液,能够促进组织生长,加快创面愈合,还具有抗菌消炎的作用;将本发明的乳液涂抹于受损皮肤表面,能够在创面表面形成保护层,起物理屏障作用,可用于小创口、擦伤、切割伤等浅表性创面及周围皮肤的护理;还可通过选用不同的原液制备具有养护功效的乳液,能够在创面恢复过程中能够消炎、修复和养护皮肤,促进黑色素分解,消除皮肤色素沉着,减少疤痕的形成。
附图说明
图1是本发明的微生物限度指标示意图。
具体实施方式
本发明的藻酸盐肌肤护理乳液的制备方法,所述方法如下:将原液和助剂按照溶液剂或软膏剂的制备方法制成透明或半透明的剂型为溶液剂或软膏剂的乳液。
其中,所述原液包括壳聚糖原液、玫瑰花原液、柠檬原液、蜂胶原液、紫锥花原液、蜗牛原液和藻酸盐原液中的至少一种。剂型为溶液剂的所述乳液其助剂包括纯化水、防腐剂、甘油和普鲁兰多糖,且防腐剂占原液重量百分比15~25%,甘油占原液重量百分比20~30%,普鲁兰多糖占原液重量百分比20~30%。剂型为软膏剂的所述乳液其助剂包括纯化水、防腐剂和聚丙烯酸钠,且防腐剂占原液重量百分比20~25%,聚丙烯酸钠占原液重量百分比20~47%。所述防腐剂包括苯甲醇、苯甲酸、水杨酸、硼酸和山梨酸中的至少一种。所述乳液其PH值范围为6~8。
实施例1:
本发明的藻酸盐肌肤护理乳液的制备方法,剂型为溶液剂的所述乳液其制备方法具体如下:
第一步,按下列重量百分比的原料备料:藻酸盐原液52%,甘油13%,普鲁兰多糖11%,防腐剂9%,余量为纯化水,上述各组分原料重量总计为100%;
第二步,将甘油、防腐剂和适量纯化水混合均匀,再水浴加热至65~80℃,得到溶液剂基质A,待用;
第三步,将普鲁兰多糖和适量纯化水混合均匀,再水浴加热至50~70℃,得到溶液剂基质B,待用;
第四步,当溶液剂基质A和溶液剂基质B处于相同水浴环境时,将溶液剂基质B呈细流状倒入溶液剂基质A中,边加边沿同一个方向搅拌,搅拌均匀后,自然降温至室温,得到混合溶液剂基质,待用;
第五步,将藻酸盐原液加入到混合溶液剂基质中,搅拌均匀,即得剂型为溶液剂的藻酸盐肌肤护理乳液。
实施例2:
本发明的藻酸盐肌肤护理乳液的制备方法,剂型为软膏剂的所述乳液其制备方法具体如下:
第一步,按下列重量百分比的原料备料:藻酸盐原液52%,防腐剂10%,聚丙烯酸钠21%,余量为纯化水,上述各组分原料重量总计为100%;
第二步,将防腐剂和适量纯化水混合均匀,再水浴加热至65~80℃,得到软膏剂基质A,待用;
第三步,将聚丙烯酸钠和适量纯化水混合均匀,再水浴加热至50~70℃,得到软膏剂基质B,待用;
第四步,当软膏剂基质A和软膏剂基质B处于相同水浴环境时,将软膏剂基质B呈细流状倒入软膏剂基质A中,边加边沿同一个方向搅拌,搅拌均匀后,自然降温至室温,得到混合软膏剂基质,待用;
第五步,将藻酸盐原液加入到混合软膏剂基质中,搅拌均匀,即得剂型为软膏剂的藻酸盐肌肤护理乳液。
藻酸盐肌肤护理乳液与伤口渗出液接触后,能够在创面表面形成保护层,为伤口愈合提供理想的湿润环境,促进伤口愈合,缓解伤口疼痛。
实施例3:
本发明的藻酸盐肌肤护理乳液的制备方法,其制备方法与实施例1基本相同,其中,所述原液为玫瑰花原液。玫瑰原液中含有的鞣酸、VC、玫瑰精油成分、天然花青素等近500种天然成分,具有抗氧化的作用,能够消炎,修复和养护皮肤,促进皮肤血液循环,增进新陈代谢,加快创面恢复;且在创面恢复过程中能够促进黑色素分解,消除皮肤色素沉着,减少疤痕的形成。
实施例4:
本发明的藻酸盐肌肤护理乳液的制备方法,其制备方法与实施例1基本相同,其中,所述原液为柠檬原液。柠檬原液具有防止和消除皮肤色素沉着的作用。
实施例5:
本发明的藻酸盐肌肤护理乳液的制备方法,其制备方法与实施例1基本相同,其中,所述原液为紫锥花原液。紫雏菊原液能够促进组织生长,有加快伤口愈合的功效;还可以抗菌,抗病毒,消炎。
实施例6:
本发明的藻酸盐肌肤护理乳液的制备方法,其制备方法与实施例2基本相同,其中,所述原液为壳聚糖原液。壳聚糖无毒、无味,对大肠杆菌、荧光假单胞菌、金黄色葡萄球菌、枯草杆菌等有良好的抑制作用,作为原液制备肌肤护理乳液,可提高乳液的成膜性,能够在创面表面形成保护层,具有抑菌、保湿功能,又不引起任何过敏刺激反应。
实施例7:
本发明的藻酸盐肌肤护理乳液的制备方法,其制备方法与实施例2基本相同,其中,所述原液为蜂胶原液。蜂胶原液能止痛止痒,不仅能消炎杀菌抗病毒,还能促进伤处恢复,对创伤、外伤、手术刀口等均有良好的治疗作用,能够止痛、抗感染、加快组织修复、限制疤痕,而且对皮肤炎症和皮肤真菌都有明显抑制和消除作用。
实施例8:
本发明的藻酸盐肌肤护理乳液的制备方法,其制备方法与实施例2基本相同,其中,所述原液为蜗牛原液。蜗牛原液是从蜗牛的粘液中萃取的精华物,蜗牛粘液具有保湿、伤口愈合、肌质再生作用,能够在创面形成保护层,起到物理屏障作用,且蜗牛粘液成分中含软骨素硫酸盐天然元素, 可代谢老化角质,防止肌肤老化,促进皮肤再生,防止某些有害菌的伤害,促进纤维母细胞合成新生,具有淡化疤痕、暗疮、斑点及缩小毛孔等功能。
对采用本发明的藻酸盐肌肤护理乳液的制备方法制备的乳液进行微生物测定,测定指标如图1所示。
本发明的藻酸盐肌肤护理乳液的制备方法,采用藻酸盐原液、壳聚糖原液、蜂胶原液、紫锥花原液或蜗牛原液作为原液制备肌肤护理乳液,能够促进组织生长,加快创面愈合,还具有抗菌消炎的作用;且将本发明的乳液涂抹于受损皮肤表面,能够在创面表面形成保护层,起物理屏障作用,可用于小创口、擦伤、切割伤等浅表性创面及周围皮肤的护理;采用玫瑰花原液或柠檬原液作为原液制备肌肤护理乳液,具有抗氧化作用,能够消炎,修复和养护皮肤,且在创面恢复过程中能够促进黑色素分解,消除皮肤色素沉着,减少疤痕的形成。
上述实施例,仅是本发明的较佳实施方式,故凡依本发明专利申请范围所述的构造、特征及原理所做的等效变化或修饰,均包括于本发明专利申请范围内。
Claims (8)
1.一种藻酸盐肌肤护理乳液的制备方法,其特征在于,所述方法如下:将原液和助剂按照溶液剂或软膏剂的制备方法制成透明或半透明的剂型为溶液剂或软膏剂的乳液。
2.根据权利要求1所述的藻酸盐肌肤护理乳液的制备方法,其特征在于,所述原液包括壳聚糖原液、玫瑰花原液、柠檬原液、蜂胶原液、紫锥花原液、蜗牛原液和藻酸盐原液中的至少一种。
3.根据权利要求1所述的藻酸盐肌肤护理乳液的制备方法,其特征在于,剂型为溶液剂的所述乳液其助剂包括纯化水、防腐剂、甘油和普鲁兰多糖,且防腐剂占原液重量百分比15~25%,甘油占原液重量百分比20~30%,普鲁兰多糖占原液重量百分比20~30%。
4.根据权利要求1所述的藻酸盐肌肤护理乳液的制备方法,其特征在于,剂型为溶液剂的所述乳液其制备方法具体如下:
第一步,按下列重量百分比的原料备料:原液50~55%,甘油10~25%,普鲁兰多糖10~15%,防腐剂7~15%,余量为纯化水,上述各组分原料重量总计为100%;
第二步,将甘油、防腐剂和适量纯化水混合均匀,再水浴加热至65~80℃,得到溶液剂基质A,待用;
第三步,将普鲁兰多糖和适量纯化水混合均匀,再水浴加热至50~70℃,得到溶液剂基质B,待用;
第四步,当溶液剂基质A和溶液剂基质B处于相同水浴环境时,将溶液剂基质B呈细流状倒入溶液剂基质A中,边加边沿同一个方向搅拌,搅拌均匀后,自然降温至室温,得到混合溶液剂基质,待用;
第五步,将原液加入到混合溶液剂基质中,搅拌均匀,即得剂型为溶液剂的肌肤护理乳液。
5.根据权利要求1所述的藻酸盐肌肤护理乳液的制备方法,其特征在于,剂型为软膏剂的所述乳液其助剂包括纯化水、防腐剂和聚丙烯酸钠,且防腐剂占原液重量百分比20~25%,聚丙烯酸钠占原液重量百分比20~47%。
6.根据权利要求1所述的藻酸盐肌肤护理乳液的制备方法,其特征在于,剂型为软膏剂的所述乳液其制备方法具体如下:
第一步,按下列重量百分比的原料备料:原液50~55%,防腐剂7~15%,聚丙烯酸钠10~25%,余量为纯化水,上述各组分原料重量总计为100%;
第二步,将防腐剂和适量纯化水混合均匀,再水浴加热至65~80℃,得到软膏剂基质A,待用;
第三步,将聚丙烯酸钠和适量纯化水混合均匀,再水浴加热至50~70℃,得到软膏剂基质B,待用;
第四步,当软膏剂基质A和软膏剂基质B处于相同水浴环境时,将软膏剂基质B呈细流状倒入软膏剂基质A中,边加边沿同一个方向搅拌,搅拌均匀后,自然降温至室温,得到混合软膏剂基质,待用;
第五步,将原液加入到混合软膏剂基质中,搅拌均匀,即得剂型为软膏剂的肌肤护理乳液。
7.根据权利要求3至6中任意一项所述的藻酸盐肌肤护理乳液的制备方法,其特征在于,所述防腐剂包括苯甲醇、苯甲酸、水杨酸、硼酸和山梨酸中的至少一种。
8.根据权利要求1所述的藻酸盐肌肤护理乳液的制备方法,其特征在于,所述乳液其PH值范围为6~8。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010331358.8A CN111450030A (zh) | 2020-04-24 | 2020-04-24 | 一种藻酸盐肌肤护理乳液的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010331358.8A CN111450030A (zh) | 2020-04-24 | 2020-04-24 | 一种藻酸盐肌肤护理乳液的制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111450030A true CN111450030A (zh) | 2020-07-28 |
Family
ID=71672133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010331358.8A Pending CN111450030A (zh) | 2020-04-24 | 2020-04-24 | 一种藻酸盐肌肤护理乳液的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111450030A (zh) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1348353A (zh) * | 1999-04-14 | 2002-05-08 | 宝洁公司 | 透明微乳液 |
| CN1679470A (zh) * | 2005-01-12 | 2005-10-12 | 凌沛学 | 用于化妆品的含海藻糖和透明质酸组合物及其制备方法 |
| CN106215220A (zh) * | 2016-09-18 | 2016-12-14 | 天津北洋百川生物技术有限公司 | 一种新型复合交联普鲁兰多糖的伤口敷料 |
| CN106260104A (zh) * | 2016-08-15 | 2017-01-04 | 陕西科技大学 | 一种复合植物油微乳液及其制备方法 |
| CN106880551A (zh) * | 2017-03-03 | 2017-06-23 | 皖南医学院 | 一种紧致滋润柔滑肌肤的身体乳及其制备方法 |
| CN107982127A (zh) * | 2017-12-08 | 2018-05-04 | 广州赛莱拉干细胞科技股份有限公司 | 一种含细胞生长因子的美白紧致乳液及其制备方法与应用 |
| JP2019023191A (ja) * | 2012-08-13 | 2019-02-14 | ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエスBASF Beauty Care Solutions France S.A.S. | 化粧品又は医薬品の保湿成分 |
-
2020
- 2020-04-24 CN CN202010331358.8A patent/CN111450030A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1348353A (zh) * | 1999-04-14 | 2002-05-08 | 宝洁公司 | 透明微乳液 |
| CN1679470A (zh) * | 2005-01-12 | 2005-10-12 | 凌沛学 | 用于化妆品的含海藻糖和透明质酸组合物及其制备方法 |
| JP2019023191A (ja) * | 2012-08-13 | 2019-02-14 | ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエスBASF Beauty Care Solutions France S.A.S. | 化粧品又は医薬品の保湿成分 |
| CN106260104A (zh) * | 2016-08-15 | 2017-01-04 | 陕西科技大学 | 一种复合植物油微乳液及其制备方法 |
| CN106215220A (zh) * | 2016-09-18 | 2016-12-14 | 天津北洋百川生物技术有限公司 | 一种新型复合交联普鲁兰多糖的伤口敷料 |
| CN106880551A (zh) * | 2017-03-03 | 2017-06-23 | 皖南医学院 | 一种紧致滋润柔滑肌肤的身体乳及其制备方法 |
| CN107982127A (zh) * | 2017-12-08 | 2018-05-04 | 广州赛莱拉干细胞科技股份有限公司 | 一种含细胞生长因子的美白紧致乳液及其制备方法与应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104288828B (zh) | 一种医用生物抑瘢除皱敷料及其制备方法 | |
| CN105194719B (zh) | 一种面部创口修复敷料、敷贴及其制备方法 | |
| CN104587518B (zh) | 一种透明质酸敷料及其制备方法 | |
| US9962402B2 (en) | Healing composition for topical application | |
| Ghaderi et al. | Topical application of honey for treatment of skin wound in mice | |
| CN103933603A (zh) | 一种壳聚糖促人表皮生长生物医用胶及其制备方法 | |
| CN108743921A (zh) | 一种预防疤痕形成的修复液及其制备方法和应用 | |
| CN107899003B (zh) | 一种低聚壳聚糖医用伤口护理膜及其制备方法 | |
| CN108815584A (zh) | 一种用于医美复合功能医用冷凝胶及其制备方法 | |
| CN109675091A (zh) | 一种消除疤痕的生物敷料及其制备方法 | |
| US11684627B2 (en) | Wound care formulations with clinically effective active ingredient content | |
| CN111450030A (zh) | 一种藻酸盐肌肤护理乳液的制备方法 | |
| CN105853252B (zh) | 一种用于皮肤热损伤的温敏水凝胶及其制备方法 | |
| KR102218008B1 (ko) | 알로에를 이용한 하이드로겔 마스크팩의 제조방법 및 이를 이용하여 제조된 하이드로겔 마스크팩 | |
| CN114984294A (zh) | 一种敷料及其制备方法 | |
| CN101417121B (zh) | 一种治疗皮肤烧烫冻伤的药物 | |
| CN112915100A (zh) | 一种用于预防和治疗瘢痕的组合物 | |
| CN116211781B (zh) | 一种预防和治疗皮肤皲裂的组合物及其制备方法与应用 | |
| CN112791093A (zh) | 治疗痤疮的透皮给药组合物及其制备方法 | |
| CN117045844B (zh) | 一种含多聚糖的敷料及其制备方法和应用 | |
| CN120381433B (zh) | 一种促进烧烫伤及其他创面愈合的抗感染药膏及其制备方法 | |
| CN120227501A (zh) | 医用透明质酸钠皮肤修护凝胶及其制备方法 | |
| WO2013122692A1 (en) | Plant extract based compositions and methods for treating chronic wounds | |
| CN111150800A (zh) | 一种修复浅表性纹路疤痕的褪疤膏及其制备方法和应用 | |
| MX2013004077A (es) | Composicion farmaceutica a base de centella asiatica (hydrocotyle asiatica l.) para el tratamiento de ulceras en miembros inferiores. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200728 |
|
| RJ01 | Rejection of invention patent application after publication |